TG Therapeutics Inc (TGTX) concluded trading on Thursday at a closing price of $37.06, with 4.3 million shares of worth about $159.35 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 57.50% during that period and on March 13, 2025 the price saw a loss of about -0.46%. Currently the company’s common shares owned by public are about 155.84M shares, out of which, 141.36M shares are available for trading.
Stock saw a price change of 5.31% in past 5 days and over the past one month there was a price change of 19.13%. Year-to-date (YTD), TGTX shares are showing a performance of 23.12% which increased to 126.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.93 but also hit the highest price of $40.31 during that period. The average intraday trading volume for TG Therapeutics Inc shares is 2.51 million. The stock is currently trading 12.05% above its 20-day simple moving average (SMA20), while that difference is up 16.87% for SMA50 and it goes to 43.54% higher than SMA200.
TG Therapeutics Inc (NASDAQ: TGTX) currently have 155.84M outstanding shares and institutions hold larger chunk of about 62.33% of that.
The stock has a current market capitalization of $5.82B and its 3Y-monthly beta is at 2.17. PE ratio of stock for trailing 12 months is 265.47, while it has posted earnings per share of $0.14 in the same period. Its PEG reads 1.70 and has Quick Ratio of 5.03 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TGTX, volatility over the week remained 7.31% while standing at 6.28% over the month.
Stock’s fiscal year EPS is expected to rise by 549.52% while it is estimated to increase by 98.39% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on October 29, 2024 offering a Buy rating for the stock and assigned a target price of $50 to it. Coverage by Goldman stated TG Therapeutics Inc (TGTX) stock as a Neutral in their note to investors on August 02, 2023, suggesting a price target of $12 for the stock. On June 26, 2023, Jefferies Resumed their recommendations, while on May 20, 2022, BofA Securities Initiated their ratings for the stock with a price target of $5. Stock get a Buy rating from B. Riley Securities on February 23, 2022.
